Wealth Enhancement Advisory Services
CMPX icon

Wealth Enhancement Advisory Services’s Compass Therapeutics CMPX Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$18.6K Sell
18,908
-64,659
-77% -$133K ﹤0.01% 4136
2026
Q2 		$195K Buy
+83,567
New +$247K ﹤0.01% 3608

Other funds holding CMPX

Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Simplicity Wealth
Simplicity Wealth Summit, New Jersey $3.43B AUM 16.22% 1-Year Est. Return
Independent Financial Group
Independent Financial Group San Diego, California $5.51B AUM 33.51% 1-Year Est. Return
McAdam LLC
McAdam LLC Philadelphia, Pennsylvania $2.66B AUM 14.82% 1-Year Est. Return
SmartHarvest Portfolios
SmartHarvest Portfolios Poulsbo, Washington $258M AUM 39.79% 1-Year Est. Return
ACT Advisors
ACT Advisors Asheville, North Carolina $308M AUM 16.31% 1-Year Est. Return
ProShare Advisors
ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return
North Star Investment Management
North Star Investment Management Chicago, Illinois $1.85B AUM 21.53% 1-Year Est. Return

Wealth Enhancement Advisory Services's CMPX Position: Q3 2026 in Review

Wealth Enhancement Advisory Services reduced its Compass Therapeutics (CMPX) stake by 77% in Q3 2026, selling an estimated $133K and leaving 18,908 shares worth $18.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4136.

Wealth Enhancement Advisory Services first reported a position in CMPX in Q2 2026 and has held it in 2 quarters since. The position peaked at $195K in Q2 2026. 23 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

  • Wealth Enhancement Advisory Services held 18,908 shares of Compass Therapeutics worth $18.6K as of Q3 2026.
  • Wealth Enhancement Advisory Services sold 64,659 Compass Therapeutics shares in Q3 2026, an estimated $133K.
  • Compass Therapeutics made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #4136 holding.
  • Wealth Enhancement Advisory Services first reported a position in Compass Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • Wealth Enhancement Advisory Services's Compass Therapeutics position peaked at $195K in Q2 2026.
  • 23 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.